AABB Standards & 21 CFR 606 cGMP: A Practical Readiness Guide
Blood banks and transfusion services in the United States operate under 21 CFR Parts 600, 606 (cGMP for blood and blood components), 610 (general biological products standards) and 630 (donor eligibility), and under the AABB Standards for Blood Banks and Transfusion Services (currently the 33rd edition).
In Short
- 21 CFR 606 sets cGMP for blood and blood components; AABB Standards extend the framework with specific operational requirements and frequently set the bar higher…
- AABB Standards 5.4 and 21 CFR 630 set out the donor eligibility determination — registration, identification, medical history, physical, infectious disease testing,…
- Components must be prepared per validated procedures, labelled per ISBT 128 (the international standard for blood, cellular therapy and tissue product…
AABB accreditation is voluntary but practically required by hospital customers and by major transplant programmes, and the AABB assessment overlaps heavily with FDA inspection scope. This guide walks the integrated cGMP/AABB framework, the recurring assessment findings, and a practical path to a defensible blood bank programme.
The integrated framework: AABB Standards over 21 CFR 606
21 CFR 606 sets cGMP for blood and blood components; AABB Standards extend the framework with specific operational requirements and frequently set the bar higher than the regulation alone. AABB Standards 5.0 (Process Control), 6.0 (Documents and Records), 7.0 (Deviation Management), 9.0 (Suppliers), 10.0 (Equipment), and the Quality System Essentials (QSEs) sit on top of the cGMP base.
More on the integrated framework: AABB Standards over 21 CFR 606
A programme written only against 606 will fail AABB assessment on the Standards-specific elements; a programme written only against AABB will not satisfy FDA on the few cGMP elements AABB does not address explicitly.
Donor eligibility, deferral and the 21 CFR 630 alignment
AABB Standards 5.4 and 21 CFR 630 set out the donor eligibility determination — registration, identification, medical history, physical, infectious disease testing, deferral periods, look-back. The 2024–2026 cycle has seen significant rule changes (HIV individual risk assessment replacing time-based deferral, updated CMV and HEV considerations) and AABB has issued aligned guidance.
More on donor eligibility, deferral and the 21 CFR 630 alignment
A donor eligibility programme that has not been refreshed since 2022 is materially out of date.
Component preparation, labelling and the ISBT 128 standard
Components must be prepared per validated procedures, labelled per ISBT 128 (the international standard for blood, cellular therapy and tissue product identification) and stored under controlled temperature with continuous monitoring. The recurring assessment finding is an ISBT 128 implementation that handles the data block correctly but breaks down on the human-readable element or the linkage between the component label, the donor file and the recipient transfusion record.
Transfusion service: compatibility, look-back and the bedside check
AABB Standards 5.16 and 21 CFR 606 set out compatibility testing, electronic crossmatch where validated, issue and the bedside identification check. The bedside identification check is the single most-discussed transfusion safety control — assessments test whether the procedure exists, whether the staff actually perform it as written, and whether the system supports it.
More on transfusion service: compatibility, look-back and the bedside check
A barcode-driven bedside check linked to the issue record is now the AABB-expected practice for routine transfusion.
A 60-Day Readiness Path
- Days 1–10
integrated 606/AABB clause map; identify divergences and apply the higher bar.
- Days 11–25
donor eligibility rule refresh against 2024–2026 changes; ensure prospective application.
- Days 26–40
ISBT 128 implementation audit with focus on linkage integrity.
- Days 41–50
bedside identification check audit at point of care.
- Days 51–60
internal audit covering the QSEs, management review and inspection/assessment readiness rehearsal.
Questions
Is AABB accreditation required by FDA?
No — AABB accreditation is voluntary. FDA inspects all licensed blood establishments under 21 CFR 600/606 regardless of AABB status. Most US blood centres maintain AABB accreditation because hospital customers and transplant programmes require it contractually.
What is the AABB Standards revision cycle?
AABB issues a new edition of the Standards approximately every two years with bulletins and interim guidance between editions. The 33rd edition is current as of mid-2026; track AABB publications for the 34th edition timeline.
Does ISBT 128 apply to cellular therapy products?
Yes — ISBT 128 is the international standard for blood, cellular therapy products and human tissue. Cellular therapy products under 1271 and under 351 should use ISBT 128 labelling for interoperability with hospital and transplant systems.
Is electronic crossmatch always acceptable?
Electronic crossmatch is acceptable per AABB Standards and FDA when the validation conditions are met — historical ABO/Rh on file, current sample tested for ABO/Rh, negative antibody screen, validated computer system with the required cross-checks. The validation file for the electronic crossmatch is a routine assessment focus.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Blood and Tissue Guide
Every unit identified. Every decision reviewed.
- Which rules reach your unit
- Receive, identify, quarantine
- Process, test, review
- Release, label, trace
Plus Evidence map and four worksheets.
Get the blood and tissue guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Blood and Tissue Guide
Every unit identified. Every decision reviewed.
Keep reading
21 CFR 1271 Readiness for Tissue and Cell Establishments
CAR T Cell Manufacturing Readiness: Chain of Identity and Release- Cord Blood Bank cGMP Readiness: 1271, BLA and FACT-NetCord
Donor Eligibility, Lookback and Deviation Readiness
EU Tissues and Cells Directive 2004/23/EC and the SoHO Regulation
FACT-JACIE Accreditation Readiness for Cell Therapy